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Evolutionary Action analyses of The Cancer Gene Atlas data sets show that many specific p53 missense and gain-of-
function mutations are selectively overrepresented and functional in high-grade serous ovarian cancer (HGSC). As
homozygousalleles, p53mutants aredifferentially associatedwithspecific lossof heterozygosity (R273; chromosome17);
copy number variation (R175H; chromosome 9); and up-stream, cancer-related regulatory pathways. The expression of
immune-related cytokineswas selectively related top53 status, showing for the first time that specific p53mutants impact,
and are related to, the immune subtype of ovarian cancer. Although the majority (31%) of HGSCs exhibit loss of
heterozygosity, a significant number (24%)maintain awild-type (WT) allele and represent anotherHGSCsubtype that is not
well defined.Usinghumanandmousecell lines,weshowthatspecific p53mutantsdifferentially alter endogenousWTp53
activity; target gene expression; and responses to nutlin-3a, a small molecular that activatesWT p53 leading to apoptosis,
providing “proof of principle” that ovarian cancer cells expressingWTandmutant alleles represent a distinct ovarian cancer
subtype.Wealso show that siRNAknock downof endogenousp53 in cells expressing homozygousmutant alleles causes
apoptosis, whereas cells expressing WT p53 (or are heterozygous for WT and mutant p53 alleles) are highly resistant.
Therefore, despite different gene regulatory pathways associated with specific p53 mutants, silencing mutant p53 might
be a suitable, powerful, global strategy for blocking ovarian cancer growth in those tumors that rely on mutant p53
functions for survival. Knowingp53mutational status inHGSCshouldpermit newstrategies tailored to control this disease.
Neoplasia (2015) 17, 789–803Introduction
High-grade ovarian cancer in women is a complex and deadly disease
characterized by tumor protein 53 (TP53; p53) mutations and genomic
instability [1–4]. Recent studies have sought to identify subtypes of
ovarian cancer for more selective and successful therapeutic strategies.Based on transcriptional profiles provided in The Cancer Gene Atlas
(TCGA), high-grade serous ovarian cancer has been divided into
specific molecular subtypes [3]. Based on genomic instability, defects in
homologous recombination, and sensitivity to platinum-based thera-
pies, two subtypes have been identified that exhibit either high or lowE-mail: joanner@bcm.edu
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high-LOH group was further divided into two groups based on high or
low sensitivity to platinum therapies. Remarkable in the high-LOH
subtype was the consistent and specific loss of chromosome 17 that
contains the TP53 locus. Not only is the loss of chromosome 17 an
apparent defining feature in high-grade serous ovarian cancer [5], these
tumors have the highest frequency of mutations in the TP53 gene than
any other tumor in women [5]. Many of these mutations confer
gain-of-function (GOF) activities that drive tumor growth independent
of wild-type (WT) p53 [6]. Molecular taxonomy studies further verify
that the molecular signature of ovarian cancer is distinct from that of
other cancers but similar to the tissue of origin [7]. These unique
characteristics of high-grade serous ovarian cancer indicate that targeting
mutant p53 as well asWTp53might provide new effective, “personalized”
therapeutic strategies. In addition, recent analyses of the TCGAdata sets, as
described herein, indicate that a significant subset of human ovarian tumor
samples expresses heterozygous, not homozygous, specific “hot-spot”TP53
mutants, raising additional questions about targeting therapies for these
tumors. Yet the functional activities of differentmutant p53 proteins in this
heterozygous subtype (compared with WT or homozygous mutant) have
not been analyzed in detail in ovarian cancer.
It is now clear from many studies and analyses of the TCGA data
sets not only that are there many p53 mutants in most human cancers
but also that not all mutants are structurally and functionally
equivalent [8–11]. For example, the R248Q mutant aggregates and is
associated with metastasis, whereas the R248W mutant does not
aggregate and is less metastatic [12]. R175H inhibits cell cycle arrest
and apoptosis in response to DNA damage, whereas the R175P only
blocks cell cycle arrest [8]. P53 mutants also exert different
phenotypic outcomes whether they are expressed with a WT p53
allele or are expressed with a null allele. For example, the pioneering
studies of Olive et al. [13] showed that mice expressing a WT p53
allele with an R175H, R270H, or null allele develop more carcinomas
and fewer lymphomas, whereas mice expressing R175H/R175H
homozygous alleles do not develop carcinomas but rather develop
more sarcomas and lymphomas [8,13]. Different p53 mutants also
interact with different partners and regulate different pathways:
R248Q and R273H (but not R175H) bind the MRE11 nuclease
leading to increased genomic instability. R175H, R248, and R273
exhibit distinct gene expression patterns related to different metabolic
states in colon cancer cells [11]; R273H appears to be highly related
to steroid metabolism [10]. Using a mouse model of ovarian cancer,
we have shown that the functional status of p53 in ovarian epithelial
tumors impacts tumor growth, metastasis, and response to steroid
hormones [14,15]. Specifically, WT p53 promotes papillary tumor
growth, whereas depletion of p53 impairs tumor growth [14]. These
results are consistent with the role of WT P53 as a regulator of cell
proliferation in normal and cancer cells [16–19]. However, the p53
null cells are highly sensitive to the steroid hormone estradiol,
undergo rampant metastases to the peritoneal cavity, and exhibit
some features of high-grade ovarian cancer [15]. Introduction of
the specific p53 mutant R172H into the mouse ovarian tumor cells
in vivo changes ovarian tumor progression, metastasis, morphology,
and response to steroids. Moreover, the tumor phenotype is markedly
more aggressive, metastatic, and similar to high-grade ovarian cancer
when homozygous R172H mutant alleles are expressed compared
with when the mutant is expressed in the presence of a WT allele
(heterozygous) (Ren et al., in revision), making these cells a valuable
resource for understanding p53 functions in ovarian cancer.Clearly, the outcomes of expressing homozygous mutant alleles that
exhibit GOF are not equivalent to outcomes associated with loss of p53
alleles [10,20,21]. This may be dictated, in part, because they can bind
to similar interacting partners but lead to diverse outcomes and greater
genomic instability [9,10]. These complexities in p53 function have
made it challenging to target p53 for therapeutic purposes. However,
several small molecules designed to maximally activate WT p53 are
currently available and lead to cell cycle arrest and apoptosis [8,10]. One
such drug, currently in clinical trials, is nutlin-3a that disrupts the
interactions of p53 with mouse double minute 2 (MDM2) leading to
increased p53 stability and activity [14,22,23]. Drugs to reactivate WT
p53 functions in mutant p53 protein, such as PRIMA-1, are available
and are also being tested [22]. However, this approach is not
straightforward [24]. Because p53 mutants acquire their own specific
functions and alter tumor functions, disrupting mutant p53 is an
alternative attractive approach [6,10]. Recent studies have shown in
breast cancer and colon cancer cells in culture that disrupting p53
expression using siRNA leads to catastrophic events and cell death in
cells expressing mutant p53 without affecting cell viability in cells with
WT p53 [25,26].
Based on these considerations, the primary goals of these studies
were 1) to use a novel computational approach, termed Evolu-
tionary Action (EAp53), which has been developed to stratify p53
mutants as high and low survival risk [27,28], to identify p53
mutants that are overrepresented in human high-grade ovarian
cancer and thus most likely to be exerting functional regulation on
tumor cell survival, metastatic activity, and responses to drug
therapies and 2) to determine the functional characteristics of the
heterozygous versus the homozygous tumor subtypes by express-
ing or silencing WTp53 or specific p53 mutants overrepresented
in ovarian cancer. The small molecule nutlin-3a was used to
maximally activate WT p53 in each context [14,23]. In addition,
p53 siRNA was used to knock down WT and mutant p53 in
human and mouse cells to determine the degree of dependence of
p53 status on cell survival in each context. Our results provide
“proof of principle” that human and mouse ovarian cancer cells
expressing one WT allele and one mutant allele are functionally
distinct from cells homozygous for either WT or mutant alleles
and clearly support previous studies [13,21]. Moreover, we show
that specific p53 mutants in the presence of a WT p53 allele
differentially regulate specific target genes and the responses of
cells to nutlin-3a. Thus, knowing the mutant status of TP53 can
be used to define the responses of cells to specific drugs and when
combined with analyses of LOH could be used to improve the
design of new therapeutic approaches.
Materials and Methods
Cell Lines
Trp53(+) cells from Pten;KrasG12D;Ptenfl/fl;Amhr2-Cre mice and
Trp53(−) cells from Trp53fl/fl;LSL-KrasG12D;Ptenfl/fl;Amhr2-Cre mice
were isolated and cultured as previously described [29]. Mice carrying the
germ line Trp53R172H mutation were generated by Dr. Guillermina
Lozano (MD Anderson Cancer Center, Houston, TX) [21]. These mice
were bred to Ptenf/f;KrasG12D;Amhr2-Cre (PK)mice described previously
[30] to obtain PK mice expressing WT Trp53 (PKP53+/+) and either
heterozygous (PKP53H/+) or homozygous mutant Trp53R172H
(PKP53H/H). Several human high-grade serous ovarian carcinoma cell
lines were used (TP53 mutation status is indicted in parentheses):
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SKOV3 (H179R), and ALST (WT). The SKOV3 cell line is an
established p53-mutant cell linewhich does not express p53 at the protein
or mRNA level and was therefore used as a negative control [31]. The
MDM2 inhibitor Nutlin-3a was synthesized by the MD Anderson
Pharmaceutical Chemistry Facility, Houston, TX. Cell lines were
incubated in a humidified atmosphere at 37°C with 5% CO2 and
cultured in RPMI 1640 media supplemented with 10% fetal bovine
serum, 100 U/ml of penicillin, and 100 μg/ml of streptomycin. For
mouse Western blot and reverse transcriptase polymerase chain reaction
(RT-PCR) analysis, cells transfected with mutant TRP53 were treated
with 10 μM nutlin-3a, a dose that was previously determined to be the
IC50 for WT TRP53 in Trp53(+) cells [14].
P53 siRNA and Cell Transfections
In experiments using transfected vector DNA, cells were transfected
with 0.20 μg of DNA with Attractene Transfection Reagent (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. P53 siRNA
experiments were performed using ON-TARGETplus Human TP53
siRNA-SMARTpool according to manufacturer protocol (Dharmacon,
Pittsburgh, PA). The optimized concentration and time points for each
cell line are indicated in the figure legends.
Determination of Cell Viability and IC50 of Nutlin-3a in
Human Ovarian Carcinoma Cell Lines
For cell viability and IC50 determinations, cells were plated at a
density of 9 × 10 [3] cells per well in 96-well plates. After 24 hours,
media samples were exchanged, and cells were treated with
incremental concentrations of nutlin-3a (5 μM, 10 μM, 25 μM,
50 μM, and 75 μM). After 24, 48, and 72 hours of incubation,
WST-1 (Roche, Pleasanton, CA) was added to each well according to
manufacturer’s protocol. The IC50 was defined as the concentration
at which a 50% reduction in cell viability occurred, as we reported
previously and verified by Annexin V FACS [32] and as documented
for these studies (Supplemental Figure 1).
P53 Activity Measurement
P53 activity was measured in lysates of cells treated with DMSO or
10 μM nutlin-3a for 24 hours for the transfected Trp53(+) and
Trp53(−)mouse tumor cell lines or for 24 hours of DMSO or nutlin-3a
at the IC50 of each cell line (above) for the human cell lines. P53 activity
was determined using the Cignal p53 Reporter (luciferase) Kit (Qiagen,
Valencia, CA) according to manufacturer’s instructions.
Western Blot Analysis
Cells were plated at a density of 20,000 cells per well in 24-well plates
and transfected with 0.25 μg of plasmid DNA using Attractene
Transfection Reagent (Qiagen, Valencia, CA) according to the
manufacturer’s protocol. Protein lysates were prepared in radio-
immunoprecipitation assay buffer. Electrophoresis of lysates (10
μg for transfected and human cells and 25 μg for nontransfected
cells to detect endogenous p53) was carried out on an 8% sodium
dodecyl sulfate polyacrylamide gel and blotted with the following
primary antibodies: P53 (1:1000 dilution, sc-6243; Santa Cruz
Biotechnology, Inc, Santa Cruz, CA), CDKN1A/p21 (1:000,
sc-397; Santa Cruz), and β-actin (1:1000 dilution, AAN01-A;
Cytoskeleton, Inc, Denver, CO). Densitometry was performed
using ImageJ v. 1.44 (Rasband, 1997 to 2012). β-Actin
densitometry values were used to account for loading differences
between lanes.Sequencing for TP53 Mutations
DNA was extracted from three human cell lines according to
manufacturer’s instructions using the Invitrogen Purelink Genomic
DNA Mini Kit (Carlsbad, CA). DNA was amplified by PCR, and
PCR products were then purified using the Invitrogen Purelink PCR
Purification Kit. Exons 5 to 9 of TP53 were then sequenced for
mutation analysis in all samples via Sanger Sequencing at the MD
Anderson Sequencing and Microarray Facility using the BigDye
Terminator v3.1 Cycle Sequencing Kits and the 3730xl DNA
Analyzer (Applied Biosystems, Carlsbad, CA). Sequences were then
analyzed using both Finch TV v1.3.1 and Lasergene SeqMan Pro.
The negative control cell line SKOV3 did not possess any mutations
in exons 5 to 9 but is known to contain a single nucleotide deletion in
exon 4. The absence of p53 protein and transcript expression in
Western blot and quantitative RT-PCR confirmed the absence of p53
activity; we therefore did not resequence SKOV3 exon 4.
Quantitative Real-Time RT-PCR
RT-PCR was performed as previously described [15]. Data are
presented as the mean ± SEM of at least three experiments performed
in triplicate. Differences among groups were analyzed by Student's
t test. *P b .05 was considered statistically significant.
Evolutionary Impact Model
To estimate the functional impact of p53mutations in human ovarian
carcinoma tissue, we used the Evolutionary Action (EA) method [27].
The EAmethodmodels the genotype-to-phenotype relationship to derive
an equation for the mutation impact, which equals to the product of the
functional importance of the mutated residue and of the amino acid
similarity of the substitution. These two terms are approximated by
Evolutionary Trace ranks and substitution matrices, respectively. The EA
scores were validated, among others, on a retrospective data set of TP53
mutants tested for transactivation activity in yeast, resulting in a nearly
linear correlation. In addition, EA was found to estimate the functional
impact of cystathionine-beta-synthase mutations and the clinical impact
of CDKN2A (p16) mutations better than current state-of-the-art
methods at the international contests organized by The Critical
Assessment of Genome Interpretation in 2011 and in 2012 to 2013,
respectively (https://genomeinterpretation.org/).
TP53 Genomic Status Analysis
As described previously [33], DNA copy number aberrations were
determined using TCGA level 1 Affymetrix SNP6.0 data, which were
processed byNexus Copy Number version 7.5 software (BioDiscovery,
Inc, Hawthorne, CA) with allele-specific copy number analysis of
tumors algorithm [34]. The frequency of each segmented region with
DNA copy number aberration for each sample group with the p53
mutation at the same amino acid (e.g. R175) was compared with all the
samples by Mann-Whitney U test to identify significant regions that
are associated with specific p53 mutant. To identify potential
upstream regulators for gene expression changes in samples with
similar p53 mutations, gene expression profile analysis using
RNAseq data from the TCGA data set was performed. Genes that
are differentially expressed between the samples with specific p53
mutation and all other samples with missense p53 mutations were
selected by simple t test (with Reads Per Kilobase Per Million
mapped reads [RPKM] N 0.1 and P value b .05). The list of genes was
then uploaded into Ingenuity Pathway Analysis for upstream
regulator analysis as described [35]. The TP53 status of the 316
high-grade serous TCGA samples has been described previously [33].
Table 1A. Frequency of Hot-Spot Mutations in Ovarian Tumors and H179R and C277F






R175H* 3.90% 3.65% 1.07
R273H* 3.12% 2.68% 1.16
Y220C* 2.60% 1.67% 1.56
R248Q 2.60% 3.26% 0.80
I195T* 2.34% 0.57% 4.09
R273C 2.08% 3.96% 0.53
V157F 1.82% 0.75% 2.43
R248W* 1.82% 2.02% 0.90
R282W 1.56% 2.33% 0.67
C176Y* 1.56% 0.48% 3.22
S241F* 1.30% 0.40% 3.28
Y163C 1.30% 0.66% 1.97
H193R* 1.30% 0.84% 1.56
G245D 1.30% 0.44% 2.95
H179R* 0.78% 1.01% 0.77
C277F* 0.26% 0.18% 1.48
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using the Catalogue of Somatic Mutations in Cancer database [36].
Results
Identification TP53 Mutants Selectively Expressed in HGSC
and Their Relation to LOH, Copy Number Variation (CNV)
and Specific Regulatory Pathways
Recent analysis of TCGA data has revealed that the TP53 gene is
mutated in the vast majority (83%) of high-grade ovarian cancers [3]. To
better understand how these mutations influence p53 function in ovarian
cancer, we applied the recently described EAmethod [27] for ranking the
functional impact of missense mutations upon protein function [28].We
calculated the EA scores for 233 different missense mutations found in a
set of 464 ovarian tumor samples from the TCGA and plotted their
distribution (Figure 1A). Compared with the background distribution
of missense mutations found in other genes, the mutations observed
within p53 are clearly different (Kolmogorov-Smirnov one-tailed test
P value = 10−96). The strong bias of these mutations toward high action
indicates a strong selection to impact p53 functions overall.Figure 1. P53 mutant expression plasmid vectors were created for mutants in serous ovarian carcinomas with high evolutionary impact
scores. (A) Calculated biological impact data (EA score) for p53 missense mutations in ovarian tumor samples (data from TCGA). Out of
464 samples, 83% had p53mutations (385). Of these, 233 were missensemutations (black and gray) and 99 are unique (black). (B) All p53
hot-spot mutations in ovarian tumor samples (TCGA) are predicted to have biologic function. One hundred ten ovarian tumors have 1 of
the 14 hot-spot mutations defined as mutations that appear in more than 1% of the ovarian tumors in TCGA. (C) All of the hot-spot
mutations are located in the DNA-binding domain.
Table 1B. Frequency of TP53 Allele Heterozygosity (TCGA, N = 316)
Copy Loss/LOH No Copy Loss/Diploid
Mutation status N (%) N (%)
WT 28 (8.9%) 17 (5.4%)
Missense 99 (31.3%) 76 (24%)
Other mutation 53 (16.8%) 37(11.7%)
2 mutant alleles NA 6 (1.9%)
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mutations (observed in more than 1% of the ovarian tumor samples).
Compared with all ovarian tumor p53 mutants, this subset has a
statistically significant shift in its distribution (Kolmogorov-Smirnov
one-tailed test = .018) away from total loss of function, suggesting
that these frequently occurring substitutions maintain some p53
function (Figure 1B). The frequency of these hot-spot mutations
within TP53 was higher in ovarian tumors than in nonovarian tumors
for 10 of the 14 mutations and was distributed equally into
conformation and DNA binding mutants (Table 1A) (Figure 1C).
Additional analyses of the TCGA data sets revealed that although
some high-grade ovarian cancers exhibit LOH (~31.3%; Table 1B),
this percentage is less than anticipated or assumed. In fact, there are a
significant number of tumors that are diploid and express one WT
and one mutant allele (~24%). Among the mutants overrepresented
in ovarian cancer, the R273H(9)/R273C(6)/R273L(2)/R273P(1)
mutation uniquely has a strong association with heterozygosity (6 out
of 18 tumors; P b .0158) compared with other mutants, including
the most frequently occurring R175H mutation (2 out of 5; P b .193).
In addition, ovarian cancer is associated with extensive CNV [2].When
CNV of tumors was assessed in relation to specific p53 mutations, theFigure 2. Analyses of p53mutants associated CNV. TCGA tumorswith t
copy number loss than tumors with all other TP53 mutations (N = 171analyses revealed that tumors with the TP53p.R175Hmutation (8 of 8;
100%) uniquely exhibited a high frequency of copy number loss on
chromosome 9 (9q22.1-9q31.1) compared with all other p53 mutants
(Figure 2). This region contains many DNA repair and tumor
suppressor genes, miRNAs, and RNA binding proteins, indicating that
their loss somehow confers a selective survival advantage in the R175H
mutant tumor cells (Suppl. Table 1). These results also indicate that the
tumors with the R175H mutant are different from others [11].
High-grade serous ovarian cancer is also uniquely associated with
specific upstream signaling pathways [7], and thus we hypothesized
that these pathways might also be related to specific p53 mutations.
Further analyses revealed that several unique and commonly activated
pathways are strongly associated with p53 mutation status (Table 2,
A and B; Suppl. Table 2). Of note, R175 has more unique pathways
associated with it than R273, perhaps reflecting the more complex
genomic mutational variance in the R175 mutants compared with the
R273 mutants that are more likely to be heterozygous for the WT
allele (see above). The unique presence of the KMT2A methyltrans-
ferase in the R175 tumors indicates that specific epigenetic signatures
likely occur in these tumor cells [37] that may involve the expression
of specific HOX genes [38–41]. In addition, the R175 mutant is
associated with immune-related genes and HOX genes, indicating
that it is related to both the immune and mesenchymal signature
subtypes [42]. The H179 mutant is linked to TGFβ1 signaling and
many inflammatory/immune-related genes, indicating that it is
perhaps specifically associated with the immune ovarian cancer
subtype [42]. The R248 mutant is highly enriched for stem-like
factors SOX2, TBX2, and TGFB2 [43,44] as well as chemokines,
cytokines, and MMP signaling. Intriguingly, R179, R248, R175, and
S241 all share high activation scores for SMARCA4, a member of thehe TP53p.R175 (N= 8)mutant had higher frequency of 9q22.1-q31.1
) and genes associated with this region (Suppl. Table 1).
Table 2B (continued)
P53 mutant Genes uniquely associated with upstream regulatory pathways related to each
p53 mutant
Immune-related
R175: CCL24, CXCL3, CD70, CYP24A1, MMP13, PPARG, TNFSF11
H179: CCL17, CCL18, CCL2, CCL25, CCL3, CD14, IL10, IL16, IL1B, MMP13
R248: CXCL1, CXCL13, CXCL5, CXCL6 HOXA5, HOXA9, MMP13, SOX2,
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[43,47]. Several mutants appear linked to retinoic acid signaling
that is known to impact the expression of HOX family genes [48],
which can mediate many tumor cell behaviors including metastasis
[40,41]. The I195T mutant is strongly associated with estradiolTable 2A. Specific p53 mutants that are frequently present in ovarian cancer are associated with
specific regulatory molecules and pathways
Mutation Upstream Regulator Molecule Type Activation
Z-Score
R175 SMARCA4 transcription regulator 3.317
P38 MAPK group 3.13
dexamethasone chemical drug 3.035
OSM cytokine 2.699
D-glucose chemical - endogenous mammalian 2.527
tretinoin chemical - endogenous mammalian 2.461
HNF1A transcription regulator 2.449
CREBBP transcription regulator 2.425
CTNNB1 transcription regulator 2.425
butyric acid chemical - endogenous mammalian 2.425
KMT2A transcription regulator 2.386
PPIF enzyme 2.236
CREB1 transcription regulator 2.234
INHBA growth factor 2.219
isoproterenol chemical drug 2.207
TO-901317 chemical reagent 2.187
alitretinoin chemical drug 2.186
estrogen chemical drug 2.183
Pka complex 2.166
CXCL12 cytokine 2.138
CEBPB transcription regulator 2.101
IL1A cytokine 2.083
tributyrin chemical drug 2
PTF1A transcription regulator 2
mycophenolic acid chemical drug 2
R273 tretinoin chemical - endogenous mammalian 2.252
decitabine chemical drug 2.415
Y220 dexamethasone chemical drug 2.611
tretinoin chemical - endogenous mammalian 2.247
R248 tretinoin chemical - endogenous mammalian 3.726
JUN transcription regulator 3.252
Cg complex 3.11
lipopolysaccharide chemical drug 3.036
IL1 group 2.914
SMARCA4 transcription regulator 2.789
HGF growth factor 2.772
OSM cytokine 2.626
EP300 transcription regulator 2.621
Vegf group 2.592
F2 peptidase 2.588
I195 beta-estradiol chemical - endogenous mammalian 4.137
Cg complex 3.256
GATA4 transcription regulator 3.237
CTNNB1 transcription regulator 3.119
MEF2C transcription regulator 2.931
TBX5 transcription regulator 2.923
estrogen chemical drug 2.905
SIM1 transcription regulator 2.828
ARNT2 transcription regulator 2.828
trichostatin A chemical drug 2.76
cyclic AMP1 chemical - endogenous mammalian 2.749
H179 TGFB1 Growth factor 8.05
Lipopolysaccharide Chemical drug 7.019
EGF Growth factor 6.497
Vegf Group 6.44
CSF2 Cytokine 6.392
SMARCA4 Transcription regulator 6.229
ERK1/2 Group 6.008
Phorbol myristate acetate Chemical drug 5.872
ERK Group 5.852
F2 peptidase 5.828
S241F SMARCA4 transcription regulator 2.778
pirinixic acid chemical toxicant 2.369
benzo(a)pyrene chemical toxicant 2.158
TBX2, TGFB2
Others
R273: HOXA3, HOXA5, HOXA9, MAGEA1, MAGEA11, MAGEC2
Y220: COL11A2, FOXD1, GCK, MIA, MMP13, NAT8B, NPY, SLC5A5, TRIM31
I195: GATA4, GDF10, INHA,OXTR, PDYN, PGR, SCARB1, STAR, TIMP4,WNT4
S241: CYP1A1, CYP1A2, CYP4A11, CYP8B1, HNF1B, HPX, LCN2, POPDC3,
SLC23A1actions as well as with the transcription factors GATA4 and TBX5
[43]. Distinctively, tumors expressing the I195, Y220, and S241
mutants do not show immune-associated factors and are different
from each other and the R179, R174, and R248 tumors. Thus, P53
mutant status is clearly related to distinct regulatory pathways, the
most notable of which appear to be associated with the immune,
TGFβ, and HOX related genes and tumor subtypes [39–42].
To assess the expression of selected upstream pathway genes, five
human cell lines in which p53 status has been determined were
analyzed: 1) ALST cells express WT TP53, 2) OVCA433 cells express
heterozygous alleles (E258K/WT), 3) OVCA420 cells are homozy-
gous for the R273H mutant allele (R273H/R273H), 4) OVCAR3
cells are homozygous for the R248Q allele (R248Q/R248Q), and 5)
SKOV3 cells are TP53 null cells with a homozygous deletion (C267)
leading to a frameshift mutation (Suppl. Table 3) [31]. Analyses of
these cell lines confirmed that expression levels of TBX2, FOXA2,
HOXA5, HOXA9, PPARG, and SMARCA4 were distinct for each cell
line and p53 mutant status (Figure 3). Expression of HOXA5 and
HOXA9 but not PPARG confirms gene expression patterns noted in
R248 tumors but not for R273 tumors (Table 2B; Suppl. Table 2).
Collectively, these analyses show 1) that specific TP53 mutants in
ovarian cancer are associated with distinct functional characteristics
including changes in CNV, LOH, and specific upstream regulatory
pathways, the most notable of which are immune and HOX gene
related, and 2) that some mutants are preferentially present with a
WT p53 allele, representing a new significant subtype of ovarian
cancer in which the functional status of the WT allele and the mutant
allele needs to be analyzed to determine if therapeutic drugs that
target p53 by either deletion of the mutant p53 or activation of WT
p53 are effective in this heterozygous tumor type.
Sensitivity of Human Ovarian Carcinoma Cells to Activation and/or
Overexpression of WT TP53 or Knockdown of Endogenous WT or
Mutant TP53. To determine if p53 status (WT, heterozygous, null,
or mutant) in human ovarian cancer cell lines determines their
expression levels and responses to nutlin-3a, cells were exposed to
nutlin-3a alone without (Figure 4A) or with exogenous WT p53
(Figure 4C). All cell lines, with the exception of the SKOV3 cells,
expressed detectable basal levels of p53 protein in the absence of
nutlin-3a. However, the basal levels of TP53 protein were higher in
the two homozygous mutant cell lines where increased stability is
known to occur [8,10] (Figure 4, A and C). Nutlin-3a increased
endogenous WT TP53 protein in ALST and OVCA433 cells but not
in null or homozygous mutant cells (Figure 4A). Nultin-3a increased
p53 promoter luciferase reporter activity in the OVCA433 cells,
whereas the elevated TP53 activity in the ALST cells was not further
Figure 3. Expression levels of genes selectively associated with specific p53 mutations in human ovarian cancer cell lines. The expression
of selected genes associated with specific p53 mutant up-stream regulatory pathways (Suppl. Table 2) in human ovarian cancer (TCGA
data sets) was analyzed in human ovarian cancer cell lines with known p53 status (WT, heterozygous, null, or homozygous mutant).
Specific genes were selectively expressed in each cell line (*P b .05 compared with ALST cells, N = 3).
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only mutant TP53 were nutlin-3a resistant as expected and exhibited
either no TP53 protein or no further increase in protein, respectively,
and no increase in p53 activity (Figure 4, A and B) [14].
Consistent with the known role of highly activated p53 in mediating
apoptosis, the ALST and OVCA433 cells that express WT TP53 were
more sensitive (IC50 = 5 and 10 μM, respectively) to low doses of
nutlin-3a in a cell viability assay than cells with no p53 (IC50 = 60 μM)
or mutant p53 (IC50 = 20 μM) (Figure 4, A; Supplemental Figure 1).
Collectively, these results show that basal activity of the WT p53 allele
is reduced in the presence of the mutant allele but that the WT allele
can be activated by nutlin-3a in this context, leading to apoptosis. Cells
that are null for TP53 or that express mutant TP53 are more resistant
to nutlin-3a. Although these data support our hypothesis that WT
TP53 can be activated in the presence of a mutant allele, results from
one human TP53 heterozygous cell line are not sufficient to make a
general conclusion.
Therefore, to test our hypothesis further, we next introduced WT
TP53 into the human cell lines using a vector expressing GFP-taggedWTTP53 (Figure 4C). GFP-WTTP53 protein was highly expressed in
all cell lines and did not have a significant effect on endogenous TP53
protein levels in the cell lines analyzed. Western blot analyses showed
that WT p53 increased the levels of CDNK1 (P21) protein, a known
target of p53, in all cell lines including those expressing homozygous
mutant p53, indicating that theWT p53 is active in the presence of the
mutant alleles. Nutlin-3a reduced p21 protein levels, indicating that
either higher levels of p53 activity are inhibitory or nutlin-3a exerts
unknown effects on p21 protein stability (Supplemental Figure 3A).
Cell viability assays showed that exogenous WT TP53 increased cell
death in each cell line except the SKOV3 p53 null cells (Figure 4D).
Moreover, we noted that the cell lines OVCA420 and OVCAR3 with
homozygous mutant alleles exhibited significantly more rapid and
extensive cell death (P b .001) compared with those (ALST and
OVCA533) with WT alleles. Thus, WT TP53 maintains p53 activity
in the presence of mutant protein, even in the absence of nutlin-3a;
adding nutlin-3a had no further effect on p53 activity and even reduced
p21 protein levels (data not shown). These results support and confirm
observations in mouse models [49].
Figure 4. Sensitivity of human ovarian carcinoma cells to nutlin-3a is
altered by the presence of endogenous and exogenous WT TP53.
(A)Western blot of lysates from human cell lines treatedwith nutlin-3a
at the IC50 for each cell line. (B) TP53 activity (luciferase assay) was
measured in lysates of cells treated with DMSO or nutlin-3a at their
predetermined IC50. (C) Western blots of GFP-tagged transfected WT
TP53 and endogenous TP53 in cells treated with DMSO or nutlin-3a at
the IC50 for each cell line. (D) Viability of cells transfected with empty
vector or WT TP53. All assays were run at least three times; Western
blots are representative of three experiments.
Figure 5. Mutant TP53 activity and nutlin-3a–induced activation of
TP53 is gene and cell context specific. (A) P53 (luciferase) activity (left
and right panels) was measured in Trp53(−) and Trp53(+) cells
following transfectionwith vectors expressing different TP53mutant
proteins (*P b .05, N= 3). Luciferase activity was expressed relative
to protein levels for eachmutant as determined byWestern blot and
densitometry analyses (Suppl. Figure 2, A–C). (B) Cell viability was
measured in Trp53(−) and Trp53(+) cells following transfection with
vectors expressing different TP53 mutant proteins and treatment
without or with 10 μM nutlin-3a (*P b .05, N = 3).
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Because only two human cell lines that we know of are
heterozygous for a WT and mutant allele and because the mutant
allele in the cell line available to us is not one highly overrepresented
in ovarian cancer, we next sought to determine the impact of specific
p53 mutants on tumor cell behaviors in the presence and absence of
WT p53. Expression vectors containing GFP-tagged WT p53 and 10mutants were created to study the impact of specific p53 mutants
(asterisk) that are present in the DNA-binding domain (Figure 1C)
that lead to either conformation changes or lack of binding. Mutants
were selected based on 1) their high frequency of expression in ovarian
cancer (R175H, R273H, Y220C) (Figure 1) [9], 2) their high frequency
of expression as heterozygous alleles in ovarian cancer (R175H, R273H,
R248W) (Table 1A and B), 3) their overrepresentation in ovarian
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(Figure 1), and 4) those occurring in human ovarian cancer cell lines
OVCAR3 (R248Q) andOVCA420 (R273H) (Suppl. Table 3) that are
used routinely for studying ovarian cancer. These vectors expressing
WT TP53 and specific TP53 mutants were transfected into our mouse
epithelial ovarian cancer cell lines that expressWT p53 (Trp53(+) or are
null for Trp53) [14]. Endogenous WT TRP53 protein is expressed at
low levels in theTrp53(+) cells (Suppl Figure 1A) as reported previously
[14]. The expression levels of GFP-WT TP53 and most GFP-mutant
TP53 proteins were elevated above those in control cells and relatively
similar in Trp53(+) and Trp53 null cells (Suppl Figure 1B) as
determined byWestern blotting with GFP and p53 specific antibodies.
To determine the relative functional activity ofWT p53 alone and in
the presence of TP53 mutants, we cotransfected a p53 consensus
promoter-luciferase reporter construct with WT or mutant TP53
expression vectors. Luciferase activity was measured (Figure 5A) and
normalized to protein levels (Supplemental Figure 2,A–C). The activityFigure 6. The sensitivity of human ovarian carcinoma cells to WT TP53
lysates from human cell lines expressing different p53 proteins (AL
OVCAR3:R248Q) following transfection with WT TP53 for 24 hours (of transfected WT TP53 in the Trp53 null cells was lower than that of
the C227F mutant. However, basal p53 activity was significantly lower
than that of WT in the presence of other mutants (Figure 5A).
Importantly and as predicted from our computational (Figure 1), gene
expression (Table 2A&B; Figure 3), and copy number analysis
(Figure 2; Suppl. Table 1), p53 activity was significantly different in
the presence of specific mutants compared with each other. Notably,
p53 activity was higher in the presence of R175H, C176Y, I195T, and
S241F, the latter two of which are uniquely expressed in ovarian cancer
cells. When p53 activity was tested in cells expressing endogenous WT
p53, basal activity was highest in the presence of exogenous WT p53
and the C277F mutant but was reduced in the presence of mutant p53.
However, two mutants overrepresented in ovarian cancer (Y220C and
S241F) and one frequently expressed as a heterozygous allele (R248W)
showed higher activity than the other mutants, indicating that these
mutants exerted less dominant negative effects on endogenousWT p53
than the other mutants. These data show that specific TP53 mutantsreintroduction correlates with p53 status. RT-PCR was performed on
ST:WT, OVCA433:WT/E248K, SKOV3:null, OVCA420:R273H, and
*P b .05, N = 3).
Figure 7. Sensitivity of mouse ovarian cancer cells to WT TP53
reintroduction correlates with p53 status. RT-PCR was performed on
lysates from mouse cell lines (p53 null, p53 WT, P53 WT/R172H, P53
R712H/R172H) transfectedwithWTTP53 for 24hours (*Pb .05,N=3).
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activity in the p53 null cells and suppress endogenous WT p53 activity
in the p53+ mouse cell lines and support the observation that basal p53
activity was lower in the heterozygous OVCA433 human cell
(Figure 4B).
To determine the effects of p53 mutants on cell viability,
additional cultures with mouse cells expressing endogenous WT
p53 were transfected with WT or specific mutant p53 and treated
with or without nutlin-3a (Figure 5B). In cells expressing WT
p53, the introduction of WT or the p53 mutants did not lead to a
major difference in cell viability, with the exception of R179H in
which cell viability was significantly higher that WT. However,
when the cells were exposed to nutlin-3a that maximally activates WT
p53, cell viability was reduced significantly when exogenous WT p53
was present. Specific mutants (C277F, R175H, I195T, and S241F)
caused even greater decreases in cell viability in the presence of
nutlin-3a, indicating that they may potentiate the effects of endogenous
p53 activity or have apoptotic functions of their own in cells whereWT
p53 is activated. These novel data support the enhanced apoptosis
mediated byWTp53 when introduced into human cell lines expressing
homozygous mutant alleles (Figure 4D).
Diverse WT p53 Regulated Gene Expression in Response to
P53 Mutants
Human cells. These results demonstrating differential effects of
mutant TP53 on WT p53 activity and cell viability led us to analyze the
expression of specific p53-target genes related to cell cycle arrest and
apoptosis in the human cell lines (Figure 6) [14]. CDKN1A mRNA is
expressed in ALST cells that have high levels of endogenous WT TP53
and is induced significantly by nutlin-3a. Expression of exogenous WT
TP53 and treatment with nutlin-3a further increased the CDKN1A
mRNA in the ALST cells. Nutlin-3a also increased CDKN1AmRNA in
the OVCA433 cells. Although exogenous WT p53 and nutlin-3a
increased CDNK1A mRNA expression, the induction by nutlin-3a was
less than that observed in the absence of exogenous WT p53. CDKN1A
was also increased following expression of WT TP53 in cells that are
TP53 null or contain homozygous TP53 mutations. However, the levels
of CDKN1A mRNA were low, and nutlin-3a did not further increase in
CDKN1A expression relative to that induced by WT TP53 alone. The
expression pattern of MDM2 in these cells was similar to that of
CDKN1A. MDM2 was induced by nutlin-3 in the ALST cells, but
expression of WT TP53 did not increase this response further. MDM2
mRNAwas also increased by the introduction ofWT TP53 in the TP53
mutant cell lines, but the levels were low and the response of these cells to
nutlin-3a was blunted or absent. These results show that expression of
CDNK1A andMDM2 are elevated in cells expressing one or two copies
of the endogenous WT allele and that cells null for p53 or that express
GOF mutants fail to express either mRNA. Because MDM2 is low in
homozygous GOF mutants, it is surprising that exogenous WT p53 did
not induce higher expression of these genes, indicating that mechanisms
to restrict their activity have been imposed. However, because MDM2 is
low, it is not surprising that nutlin-3a had no effect.
Because WT p53 dramatically reduced cell viability in the
OVCA420 and OVCAR3 cells compared with the ALST,
OVCA433, and SKOV3 cells and because cell viability was not
strictly related to the levels of p21 mRNA (Figure 6) or protein
(Suppl. Figure 3A), we sought to determine what mechanisms other
than, or in addition to, cell cycle arrest might mediate these effects.
Therefore, we analyzed the expression of genes that mediate apoptosis(PUMA) and caspase 3 (CASP3) as well as a factor (DNAJC3)
involved in the unfolding protein response (UPR) that has been
shown to increase in response to specific drugs [50]. As shown
(Figure 6), PUMA was induced markedly in the null and mutant cells
lines but not in the cell lines expressing WT p53, indicating that WT
p53 can induce this apoptotic related factor in the presence of GOF
mutants. The response to nutlin-3a may be nonspecific because
MDM2 levels are low. Surprisingly, CASP3 is not induced in the
mutant cells but is increased in the heterozygous cell line. The marked
increase in DNAJC3 suggests that the exogenous WT p53 impacts
the UPR in the presence of the homozygous mutants.
Mouse cells. To determine if WT TP53 had a similar effect on
p53 activity in mouse ovarian cancer cells, WT p53 was introduced
into our mouse ovarian cancer cell lines that are either homozygous or
heterozygous for the p53 R172H mutation [15], which is equivalent
to the human R175H mutation. As shown, Cdkn1a and Mdm2
expression levels were low and unresponsive to nutlin-3a in the
absence of exogenous WT p53 but increased significantly following
WT TP53 expression in both the p53 R172H heterozygous and
homozygous cells and rendered these cells responsive to nutlin-3a
(Figure 7). These results indicate that the mouse tumor cells are less
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indicating that WT TP53 is active at low levels in the presence of
mutant p53 in these mouse ovarian cancer cells (Figure 6).
To further investigate the impact of specific p53 mutants on
endogenous WT p53 transcriptional activities, we analyzed the
expression of selected p53 target genes (Cdkna1 and Hmgb2) in
Trp53+ mouse tumor cells expressing either WT p53 or specific p53
mutants (Figure 8). Cdkn1a (p21) mRNA was elevated in the
Trp53+ cells as reported previously [14]; expression of exogenous
WT TP53 did not further increase in levels of p21 mRNA.
Furthermore, expression R175H, R273H, and C176Y did not alter
p21 mRNA levels in the Trp53+ cells, indicating that they did not
impact the functional activity of endogenous WT p53 on this gene.
However, R248W, H179R, and S241F mutants significantly
decreased the expression of p21 mRNA, indicating that they exert
dominant negative effects on endogenous p53 activity in these cells.
Hmgb2 is a p53-suppressed gene encoding a chromatin-associated
high mobility–group protein that plays a role in DNA unwinding
[51]. WT, R175H, and S241F significantly repressed the expression
of Hmgb2 mRNA, suggesting that these mutants retain some p53
activity on this gene in this context or possibly enhance the functions
of endogenous p53 [8]. None of the mutants altered Mdm2 or Brca1
expression levels, indicating that the effects of mutants are gene
specific (data not shown).
Nutlin-3a increased the levels of p21 mRNA three-fold in the
Trp53+ cells (Figure 8; empty vector); this induction was not
increased further by exogenous WT TP53 or R175H. However,
nutlin-3a–mediated induction of p21 mRNA was enhanced
significantly by several mutants (R248W, H179R, R273H, S241F,
and C176Y), suggesting that they enhance endogenous WT p53
activation and/or stabilization in this context, perhaps by their highFigure 8. P53 mutants differentially impact p53 target gene expres
P53-responsive genes were analyzed by RT-PCR in untreated Trp53+
proteins (left panel). Nutlin-3a induction of p53-responsive genes was
into Trp53(+) cells (right panel). Results in the nutlin-3a–treated cells
for 24 hours compared with cells transfected with control empty vecaffinity for MDM2 and protectingWT p53 from degradation. Except
for S241F, these mutants also enhanced the suppression of Hmgb2 in
the presence of nutlin-3a. These data indicate that endogenous
p53-mediated induction of p21 mRNA and suppression of Hmgb2
are maintained or even enhanced by specific p53 mutants. These
results further support our hypothesis that, in the heterozygous
ovarian cancer subtype, WT TP53 can be activated and its activation
by nutlin-3a can even be enhanced, not suppressed, by specific
mutants. These results support those observed in the heterozygous
human cell lines and highlight the usefulness of nutlin-3a as a
therapeutic agent for patients with heterozygous ovarian tumors.
Tumor Cell Functions Following Depletion of Mutant p53
Although nutlin-3a appears to be a useful and effective drug to
activate WT TP53 and promote apoptosis of ovarian tumor cells
(Figure 4) [14,32], it does not impact ovarian tumor cells expressing
homozygous mutants (Figure 4) which appear to have acquired
specific mechanisms for maintaining cell survival [6,8]. Therefore, we
next determined if knocking down mutant TP53 using siRNA
(targeting both WT and mutant p53) in the human and mouse cells
lines would alter their cell survival–promoting functions. Following
transfection of p53 siRNA, successful depletion of TP53 protein and
its target gene p21 was verified in each cell line by Western blot
analyses (Suppl Figure 3, B–D), and changes in cell viability were
analyzed (Figure 9A). Specifically, human and mouse cells with WT
p53 or those heterozygous for WT and mutant alleles or those that
were p53 null were less sensitive to p53 siRNA treatment than were
the homozygous TP53 mutant cell lines (Figure 9A). Moreover, the
mouse cell lines were less sensitive to p53 siRNA knockdown of p53
and expression of p21 (Suppl. Figure 3, C and D). OVCAR3 cells
expressing the R248Q mutant p53 were more sensitive to siRNAsion and responses to nutliin-3a in mouse Trp53(+) tumor cells.
cells transfected with vectors expressing different TP53 mutant
analyzed by RT-PCR following transfection of mutant TP53 vectors
are presented as the fold change of induction with 10 μM nutlin-3a
tor alone (EV, lane 1; *P b .05, N = 3).
Figure 9. Human and mouse ovarian cancer cells with WT or mutant p53 exhibit distinct responses to depletion of p53. Human and mouse
ovarian cell lines were treated with siRNA at doses and times determined to reduce cell viability. Human and mouse ovarian cancer cell
lines were transfected with 20 nm p53 siRNA. Human breast cancer cell lines that were resistant to 20 nm were transfected with 50 nM
P53 siRNA. Cell viability and gene expression patterns were analyzed by methods described above. (*P b .05, N = 3).
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Human breast cancer cells with R175H (SK-BR-3) and L194F
(T47D) mutant p53 were more sensitive than cells with WT p53 as
previously described [26]. However, the breast cancer cells were more
resistant than the ovarian cancer cells to siRNA depletion even at
50 nM p53 siRNA. These results indicate that the presence of
homozygous R248Q, R273H, or R172H alleles confers a survival
advantage and dependency on the mutant p53 protein compared with
the other cell lines. To determine the impact of p53 knock down on
gene expression in the human cells, RT-PCR was performed to
measure p53 target genes, and genes involved in apoptosis and cell
stress responses (Figure 9B). CDKN1A was decreased in ALST cells
following silencing of WT p53 expression, whereas there was no
change in cells with heterozygous mutant p53. By contrast, CDKN1A
expression was increased by p53 siRNA in OVCA420 cells but to a
lesser degree in OVCAR3 cells [52]. CASP3, a mediator of apoptosis,
and DNAJC3, a component of the UPR stress pathway, were highly
induced in response to p53 siRNA in OVCA420 (10- and 179-fold,
respectively) and OVCAR3 (640- and 250-fold, respectively) but not
in cells expressing WT p53. PUMA was increased in the OVCA420
cells but was low in the OVCAR3 cells, indicating that the cells
homozygous for the R273H mutation differ from those with the
R248Q mutation in this context. Furthermore, p53 siRNA reduced
expression of the upstream regulatory factor SMARCA4 in cells
expressing WTp53, had no effect in the p53 null cells, and mayincrease expression in the R273H homozygous mutant cells. When
mouse cells homozygous for the R172H allele were exposed to p53
siRNA, Casp3 but not Cdkn1a expression was increased and is
associated with decreased cell viability. Expression of Puma and
Dnajc3 was low and not altered, indicating that other pathways
appear to be activated in these cells, perhaps relating to the fact that
the mouse cells exhibit less genomic instability and are not as
susceptible to the UPR. As in the human cells, p53 siRNA reduced
expression of Smarca4 in mouse cells expressing WT p53 but did not
alter its expression in the R172H homozygous mutant cells
(Figure 9B), indicating that Smarca4 may be a p53-regulated gene.
Collectively, these data indicate that cells heterozygous for mutant
and WT p53 respond to nutlin-3a and exhibit increased p53 activity,
target gene expression, and apoptosis. Conversely, ovarian cancer cells
expressing WT p53 can withstand acute removal of p53 and avoid
rapid cell death. However, cells dependent on mutant p53 are highly
sensitive to either the 1) the removal of the mutant p53 protein
leading to a stress-induced cell death or 2) an increase in WT p53 and
consequent activation of p53 mediated apoptosis, including increased
p21 protein levels.
Discussion
High-grade epithelial ovarian cancer, unlike other epithelial cancers,
is unique because of genomic instability and the vast number of TP53
mutations that occur in this disease. Hence, it has become imperative
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and response to therapeutic drugs. Using evolutionary computer
analyses, selected human ovarian cancer cell lines that are
homozygous or heterozygous for specific mutants, and tumor cell
lines derived from our mouse models expressing WT or mutant
alleles, we document herein that 1) specific missense and GOF
mutations that are predicted to have biologic function are
overrepresented in ovarian cancer; 2) a subset of the most highly
represented TP53 mutations in ovarian tumors is heterozygous for a
WT and mutant TP53 allele and, hence, represent a specific ovarian
cancer subtype not previously analyzed in detail; 3) the R273H
mutant in particular is more strongly linked to heterozygosity than
other mutants; 4) the R175H mutant is uniquely associated with
CNV and allelic LOH on chromosome 9; 5) upstream pathways
associated with specific TP53 mutants show distinct gene expression
differences; 6) p53 activity (luciferase activity, target gene expression,
and cell viability in response to nutlin-3a) in tumor cells expressing
WT and mutant heterozygous alleles differs from that in cells
homozygous for WT or mutant alleles; and 7) cells with homozygous
mutant alleles are more sensitive to p53 siRNA than are cells with
WT TP53 and exhibit specific apoptotic and UPR-related genes but
also show distinct differences in the expression of specific genes
associated with specific regulatory pathways.
Specifically, by interrogating the ovarian cancer TGCA data sets in
the context of specific p53 mutations, we have revealed several novel
findings relevant to TP53mutations, their prevalence in ovarian cancer,
and their links to CNV and heterozygosity. The data sets also show that
upstream pathways [7] linked to specific TP53 mutations exhibit
striking differences as well as a few similarities. For example, the R273H
mutation has few upstream pathways that are unique, whereas the
I195Tmutations showhigh associationwith estrogen receptor signaling
and the R175H mutation is linked to multiple pathways, including
retinoic acid signaling. In addition, we show that several TP53
mutations, including R175H, R273H, Y220C, I195T, and S241F, are
overrepresented in ovarian cancer and that each exhibits specific
functional differences when expressed endogenously or exogenously in
the tumor cells. In particular, human tumors with the R175Hmutation
are associated with a high frequency of CNV in a specific region of
chromosome 9. That this occurs in eight of eight tumors analyzed
suggests that LOH in this region of chromosome 9 somehow confers
early survival advantages to these R175H-expressing tumors. Many of
the 124 genes identified in the 9q22.1-33.1 region control DNA repair,
cell cycle progression, or tumor suppressor functions; many others are
microRNAs that can have global effects in cells.
The R273H mutation that is strongly linked to heterozygosity
(four of nine; P b .016) in ovarian tumors also exhibits fewer unique
upstream regulatory pathways compared with tumors expressing
R175H, R179H, R248Q, and I195T. The presence of both a WT
and R273H allele in the tumor samples most likely renders them
similar to cells expressing only WT TP53 alleles; R273H enhanced
nutlin-3a–mediated induction of Cdnk1a and suppression of Hmgb2
inmouse cells expressingWTp53. Evidence presented herein in human
andmouse ovarian cancer cells supports previous studies of other tumor
types [13,21] and our hypothesis that ovarian tumor cells expressing
heterozygous p53 alleles belong to a specific ovarian cancer subtype with
specific functional characteristics thatmay also be dependent on the p53
mutant that is expressed. For example, although the human ovarian cell
line that expresses the R273H mutation is homozygous for the mutant
allele, data from the OVCA433 cell line expressing one WT allele andone mutant allele show that the presence of one WT allele impacts
tumor cell behavior such that the cells respond more like cells withWT
p53. Specifically, the human OVCA433 cells exhibit increased p53
(luciferase) activity and Cdnk1a andMdm2 expression and reduced cell
viability in response to nutlin-3a, all targets of WT p53. Moreover, the
responses of the OVCA433 cells to nutlin-3a were highly similar to
those of the ALST cells expressing only WT TP53. Conversely, the
human OVCA420 and OVCAR3 cells that are homozygous for
R273H and R248Q alleles, respectively, do not respond or show
reduced responses to nutlin-3a.
As a control, we tested whether or not introducing WT TP53 into
the human cell lines would alter their responses without or with
nutlin-3a. As expected, WT p53 increased p53 target gene expression
(Cdnk1a, Mdm2) in each cell line. Although the levels of mRNA were
much lower in the OVCA420 and OVCAR3 cells, the fold induction
was highly significant, and these cells exhibited more dramatic cell
apoptosis than the ALST or OVCA433 cells in response to the
exogenous p53. This may be related, in part, to the elevated levels of
p21 protein observed in the OVCA420 and OVCAR3 cells. That the
elevated levels of p21protein in the SKOV3 cells are not related to
enhanced apoptosis further reinforces the distinct phenotype of p53
null cells. That induction of CASP3 was far greater in the ALST or
OVCA433 cells than in the homozygous mutant cells indicates that
mechanisms other than, or in addition to, increased expression of
CASP3 are operative in these mutant cells. The increase in PUMA
suggests that WT p53 selectively increases this apoptotic-related gene
in the homozygous mutant cells. It is also possible that the WT p53
blocks specific survival pathways in the mutant cells. To analyze this,
we treated each cell line with p53 siRNA to deplete endogenous
mutant p53. Whereas the cells expressing WT TP53 showed some
increase in cell death, the homozygous mutant cells exhibit more
dramatic increases in apoptosis. In the homozygous mutant cells but
not in the cells expressing WT TP53, expression of DNAJC3, a gene
involved in the unfolded protein stress response, was dramatically
induced; CASP3 also increased, but the TP53 target PUMA was not
induced. Collectively, these results indicate that WT p53 is functional
in the mutant cells and appears to induce a specific set of genes that,
combined with the loss of mutant p53, leads to distinct cellular
responses and cell death in the homozygous mutant cells.
Data obtained in parallel from our mouse ovarian cancer cell lines
extend and provide further support for the distinct functional
activities of tumor cells expressing heterozygous versus homozygous
53 alleles and thus emphasize the importance of understanding the
functional characteristics of the heterozygous tumor phenotype.
Specifically, the data obtained in the mouse ovarian cancer cells
document that although all of the p53 mutants tested suppressed
basal p53 activity as measured by luciferase assays with a “consensus”
p53 promoter element, some were more potent than others. In
addition, the mutants exerted their own specific effects on p53 target
gene expression in the Trp53+ cells. For example, we document
that one p53 GOF and DNA binding mutant, R248W, which is
overrepresented in ovarian cancer, suppressed endogenous WT
p53-mediated luciferase activity and Cdkn1a mRNA expression but
had no effect on Hmgb2 expression and unexpectedly enhanced
nutlin-3a activation of Cdkn1a mRNA expression and suppressed
Hmgb2 expression. In addition, the H179R mutant exerted similar
effects to those of the R248W mutant on WT p53 activity and gene
expression, indicating that these distinctly different mutants can
impact WT p53 activity in a similar manner in this context, perhaps
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provides another interesting example. It is highly overrepresented in
ovarian tumors, its functional activities have not been analyzed, and
no human ovarian cancer cell lines express this mutant. However, the
S241F mutant 1) suppresses WT p53 activity in luciferase assays but
not as much as other mutants, 2) suppresses Cdkn1a mRNA
expression, and 3) more potently suppresses Hmgb2 mRNA than
WT p53 in the Trp53+ cells. Moreover, S241F enhances nutlin-3a
activation of Cdkn1a expression but does not alter nutlin-3a effects
on Hmgb2 expression. Thus, the S241F mutant exerts both p53
activity and p53 antagonistic activity depending on context. Maybe it
binds MDM2, protecting WT p53 from degradation. Collectively,
these data show that specific p53 mutants can modulate WT p53
functional activities and thus tumor cell behavior in response to
nutlin-3a, thereby confirming and extending results of others
showing that different p53 mutants are not functionally equivalent
[51,53]. The ability of some mutants to retain WT p53 activity likely
relates to their ability to bind similar p53 response elements in the
target genes, whereas the ability of mutants to block p53 activity likely
prevents WT p53 from targeting p53 consensus sites on target genes.
Furthermore, we have recently generated mice expressing the
R172H (R175H in humans) allele. Tumors expressing either
heterozygous or homozygous R172H alleles develop rapidly in
these mice and exhibit markedly different phenotypes (Ren et al., in
revision). Herein we show that cells derived from the heterozygous
tumors or from tumors homozygous for the R172H allele exhibit
increased p53 activity, as measured by Cdkn1a and Mdm2 mRNA
expression, in response to exogenous WT p53 expression and
nutlin-3a treatment (Figure 5). Moreover, the mouse data show
clearly that cells homozygous for the R172H/R172H mutant protein
do not totally suppress exogenous WT p53 activity. Furthermore,
when the R175Hmutant was expressed in the Trp53+ cells (Figures 2
and 3), it did not suppress basal or nutlin-3a Cdnk1a induction. Like
the human cells, the homozygous R172H mutant mouse cells are
sensitive to p53 siRNA, exhibit increased Casp3, and undergo cell
death. That cell death is not as dramatic in the mouse cells as in the
human cells may be related to the absence of an unfolded protein
response and lack of induction of Dnajc3 or to the different genetic
backgrounds of these cells. Like the human cells, the mouse cells
expressing WTp53 are relatively insensitive to p53 siRNA.
Conclusions
These studies document that specific p53 missense and GOF
mutations are selectively overrepresented in high-grade ovarian
cancer. As homozygous alleles, specific mutants are differentially
associated with specific LOH (chromosome 17) [5], CNV (R175H;
chromosome 9), and specific upstream (SMARCA4, estrogen,
retinoic acid, TGFβ) and cancer-related (TBX2/5, HOXA5,
HOXA9, and PPARG) regulatory pathways. Of particular relevance,
expression of immune-related cytokines was selectively related to p53
status, showing for the first time that p53 mutant status impacts, and
is related to, the immune subtype [42,54,55] of ovarian cancer.
Specific mutants differentially linked to retinoic acid signaling and
specific HOX gene expression might provide potential targets for
novel therapeutic strategies [40,48]. Each mutant also differentially
alters endogenous WT p53 activity, target gene expression, and
responses to nutlin-3a, providing “proof of principle” that ovarian
cancer cells expressing both a WT and mutant allele represent a
distinct ovarian cancer subtype. Using human ovarian cancer cell lineswith known p53 status, we show that 1) nutlin-3a activates WT p53
in the presence of mutant p53; 2) reintroduction of WT p53 into
human cell lines that are homozygous for specific p53 mutants leads
to target gene expression, elevated levels of p21 protein, and apoptosis
even without nutlin-3a; and 3) knock down of endogenous p53 in
cells expressing homozygous mutant alleles causes a stress-induced
UPR and apoptosis. Despite different gene regulatory pathways
associated with specific mutants, silencing mutant p53 might be a
suitable and powerful strategy for blocking tumor growth in ovarian
cancers that rely on mutant p53 functions for survival [6,25,26].
Thus, knowing the p53 status of human ovarian cancer cells and
using drugs that either activate WT p53 or inactivate mutant p53
may provide alternative strategies for managing tumor growth.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.10.003.
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